title: A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.
authors.forename: Rakesh
authors.initials: R
authors.lastname: Popat
authors.forename: Torben
authors.initials: T
authors.lastname: Plesner
authors.forename: Faith
authors.initials: F
authors.lastname: Davies
authors.forename: Gordon
authors.initials: G
authors.lastname: Cook
authors.forename: Mark
authors.initials: M
authors.lastname: Cook
authors.forename: Peter
authors.initials: P
authors.lastname: Elliott
authors.forename: Eric
authors.initials: E
authors.lastname: Jacobson
authors.forename: Todd
authors.initials: T
authors.lastname: Gumbleton
authors.forename: Heather
authors.initials: H
authors.lastname: Oakervee
authors.forename: Jamie
authors.initials: J
authors.lastname: Cavenagh
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects; D000069286:Bortezomib; D003404:Creatinine / Q000097:blood; D003681:Dehydration / Q000209:etiology; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D012074:Remission Induction; D000077185:Resveratrol; D016879:Salvage Therapy; D013267:Stilbenes / Q000008:administration & dosage / Q000009:adverse effects; D017211:Treatment Failure; D014839:Vomiting / Q000139:chemically induced / Q000150:complications
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013267:Stilbenes; D000069286:Bortezomib; D003404:Creatinine; D000077185:Resveratrol